EMTRIVA Safely and Effectively

Total Page:16

File Type:pdf, Size:1020Kb

EMTRIVA Safely and Effectively HIGHLIGHTS OF PRESCRIBING INFORMATION Creatinine Clearance (mL/min) These highlights do not include all the information needed to use <15 mL/min EMTRIVA safely and effectively. See full prescribing information ≥50 30–49 15–29 Formulation or on for EMTRIVA. mL/min mL/min mL/min hemodialy ® EMTRIVA (emtricitabine) capsule, for oral use sisa ® EMTRIVA (emtricitabine) oral solution 200 mg Capsule 200 mg every 200 mg every 200 mg every every 96 Initial U.S. Approval: 2003 (200 mg) 24 hours 48 hours 72 hours hours WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH 60 mg STEATOSIS and POST TREATMENT EXACERBATION OF 240 mg every 120 mg every 80 mg every Oral Solution every HEPATITIS B 24 hours 24 hours 24 hours (10 mg/mL) 24 hours (24 mL) (12 mL) (8 mL) See full prescribing information for complete boxed warning. (6 mL) • Lactic acidosis and severe hepatomegaly with steatosis, a. Hemodialysis Patients: If dosing on day of dialysis, give dose including fatal cases, have been reported with the use of after dialysis. nucleoside analogs. (5.1) -----------------------DOSAGE FORMS AND STRENGTHS-------------------- • Emtriva is not approved for the treatment of chronic Hepatitis • Capsules: 200 mg (3) B virus (HBV) infection. Severe acute exacerbations of Hepatitis B have been reported in patients who have • Oral solution: 10 mg per mL (3) discontinued EMTRIVA. Hepatic function should be monitored closely in patients coinfected with HIV-1 and HBV. --------------------------------CONTRAINDICATIONS----------------------------- If appropriate, initiation of anti-Hepatitis B therapy may be EMTRIVA is contraindicated in patients with previously demonstrated warranted. (5.2) hypersensitivity to any of the components of the products. (4) ---------------------------RECENT MAJOR CHANGES--------------------------- ----------------------------WARNINGS AND PRECAUTIONS------------------- Indications and Usage (1) 11/2012 Warnings and Precautions • Products with same active ingredient: Do not use with other Coadministration with Other Products (5.3) 11/2012 emtricitabine-containing products (e.g., ATRIPLA, COMPLERA, Immune Reconstitution Syndrome (5.6) 11/2011 STRIBILD, and TRUVADA). (5.3) • Redistribution/accumulation of body fat: Observed in patients ---------------------------INDICATIONS AND USAGE----------------------------- receiving antiretroviral therapy. (5.5) EMTRIVA, a nucleoside analog HIV-1 reverse transcriptase inhibitor, is • Immune reconstitution syndrome: May necessitate further indicated in combination with other antiretroviral agents for the evaluation and treatment. (5.6) treatment of HIV-1 infection. (1) -------------------------------ADVERSE REACTIONS------------------------------ -------------------------DOSAGE AND ADMINISTRATION---------------------- Most common adverse reactions (incidence ≥10%) are headache, • EMTRIVA may be taken without regard to food. (2.1) diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal • Adult Patients (18 years of age and older) (2.2): dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis. Skin hyperpigmentation was very common (≥10%) in pediatric patients. • EMTRIVA capsules: one 200 mg capsule administered once (6) daily orally. To report SUSPECTED ADVERSE REACTIONS, contact Gilead • EMTRIVA oral solution: 240 mg (24 mL) administered once Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or daily orally. www.fda.gov/medwatch. • Pediatric Patients (0–3 months of age) (2.3): ---------------------------USE IN SPECIFIC POPULATIONS-------------------- • EMTRIVA oral solution: 3 mg/kg administered once daily • Nursing mothers: Women infected with HIV should be instructed orally. not to breast feed. (8.3) • Pediatric Patients (3 months through 17 years) (2.4): • Pediatrics: Dose adjustment based on age and weight. (2.3, 2.4, 12.3) • EMTRIVA oral solution: 6 mg/kg up to a maximum of 240 mg (24 mL) administered once daily orally. See 17 for PATIENT COUNSELING INFORMATION and FDA- approved patient labeling. • EMTRIVA capsules: for children weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally. Revised: November 2012 • Dose interval adjustment in adult patients with renal impairment (2.5): Gilead Sciences 1 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B 1 INDICATIONS AND USAGE 10 OVERDOSAGE 2 DOSAGE AND ADMINISTRATION 11 DESCRIPTION 2.1 Recommended Dose 12 CLINICAL PHARMACOLOGY 2.2 Adult Patients (18 years of age and older) 12.1 Mechanism of Action 2.3 Pediatric Patients (0–3 months of age) 12.3 Pharmacokinetics 2.4 Pediatric Patients (3 months through 17 years) 12.4 Microbiology 2.5 Dose Adjustment in Adult Patients with Renal 13 NONCLINICAL TOXICOLOGY Impairment 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 3 DOSAGE FORMS AND STRENGTHS 14 CLINICAL STUDIES 4 CONTRAINDICATIONS 14.1 Treatment-Naive Adult Patients 5 WARNINGS AND PRECAUTIONS 14.2 Treatment-Experienced Adult Patients 5.1 Lactic Acidosis/Severe Hepatomegaly with Steatosis 14.3 Pediatric Patients 5.2 Patients Coinfected with HIV-1 and HBV 16 HOW SUPPLIED/STORAGE AND HANDLING 5.3 Coadministration with Related Products 17 PATIENT COUNSELING INFORMATION 5.4 New Onset or Worsening Renal Impairment 17.1 Information for Patients 5.5 Fat Redistribution 5.6 Immune Reconstitution Syndrome 6 ADVERSE REACTIONS *Sections or subsections omitted from the full prescribing information 6.1 Adverse Reactions from Clinical Trials Experience are not listed 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Patients with Impaired Renal Function Gilead Sciences 2 FULL PRESCRIBING INFORMATION WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5.1)]. EMTRIVA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of EMTRIVA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued EMTRIVA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue EMTRIVA. If appropriate, initiation of anti-hepatitis B therapy may be warranted [See Warnings and Precautions (5.2)]. 1 INDICATIONS AND USAGE EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection: • EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products [See Warnings and Precautions (5.3)]. • In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history [See Clinical Pharmacology (12.4)]. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dose EMTRIVA may be taken without regard to food. 2.2 Adult Patients (18 years of age and older) • EMTRIVA capsules: one 200 mg capsule administered once daily orally. • EMTRIVA oral solution: 240 mg (24 mL) administered once daily orally. 2.3 Pediatric Patients (0–3 months of age) • EMTRIVA oral solution: 3 mg per kg administered once daily orally. 2.4 Pediatric Patients (3 months through 17 years) • EMTRIVA oral solution: 6 mg per kg up to a maximum of 240 mg (24 mL) administered once daily orally. Gilead Sciences 3 • EMTRIVA capsules: for children weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally. 2.5 Dose Adjustment in Adult Patients with Renal Impairment Significantly increased drug exposures were seen when EMTRIVA was administered to subjects with renal impairment [See Clinical Pharmacology (12.3)]. Therefore, the dosing interval or dose of EMTRIVA should be adjusted in patients with baseline creatinine clearance less than 50 mL per min using the following guidelines (see Table 1). The safety and effectiveness of these dose adjustment guidelines have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients. Table 1 Dose Adjustment in Adult Patients with Renal Impairment Creatinine Clearance (mL/min) <15 mL/min Formulation ≥50 mL/min 30–49 mL/min 15–29 mL/min or on hemodialysisa 200 mg Capsule 200 mg every 200 mg every 200 mg every every (200 mg) 24 hours 48 hours 72 hours 96 hours 240 mg every 120 mg every 80 mg every 60 mg every Oral Solution 24 hours 24 hours 24 hours 24 hours (10 mg/mL) (24 mL) (12 mL) (8 mL) (6 mL) a. Hemodialysis Patients: If dosing on day of dialysis, give dose after dialysis. Although there are insufficient data to recommend a specific dose adjustment of EMTRIVA in pediatric patients with renal impairment, a reduction in the dose and/or an increase in the dosing interval similar to adjustments for adults should be considered. 3 DOSAGE FORMS AND STRENGTHS EMTRIVA is available as capsules and oral solution. EMTRIVA capsules, containing 200 mg of emtricitabine, are size 1 hard gelatin capsules with a blue cap and white body, printed with “200 mg” in
Recommended publications
  • Truvada (Emtricitabine / Tenofovir Disoproxil)
    Pre-exposure Prophylaxis (2.3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Recommended dose in HIV-1 uninfected adults: One tablet TRUVADA safely and effectively. See full prescribing information (containing 200 mg/300 mg of emtricitabine and tenofovir for TRUVADA. disoproxil fumarate) once daily taken orally with or without food. (2.3) TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Recommended dose in renally impaired HIV-uninfected Initial U.S. Approval: 2004 individuals: Do not use TRUVADA in HIV-uninfected individuals if CrCl is below 60 mL/min. If a decrease in CrCl is observed in WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH uninfected individuals while using TRUVADA for PrEP, evaluate STEATOSIS, POST-TREATMENT ACUTE EXACERBATION OF potential causes and re-assess potential risks and benefits of HEPATITIS B, and RISK OF DRUG RESISTANCE WITH USE OF continued use. (2.4) TRUVADA FOR PrEP IN UNDIAGNOSED HIV-1 INFECTION -----------------------DOSAGE FORMS AND STRENGTHS-------------------­ See full prescribing information for complete boxed warning. Tablets: 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100 Lactic acidosis and severe hepatomegaly with steatosis, mg/150 mg of emtricitabine and tenofovir disoproxil fumarate . (3) including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (5.1) --------------------------------CONTRAINDICATIONS-----------------------------­ TRUVADA is not approved for the treatment of chronic Do not use TRUVADA for pre-exposure prophylaxis in individuals with hepatitis B virus (HBV) infection. Severe acute unknown or positive HIV-1 status. TRUVADA should be used in exacerbations of hepatitis B have been reported in patients HIV-infected patients only in combination with other antiretroviral coinfected with HIV-1 and HBV who have discontinued agents.
    [Show full text]
  • Download Article PDF/Slides
    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
    [Show full text]
  • Zero Dollar Cost Share – Generic Tenofovir Disoproxil Fumarate 300 Mg P&T Approval Date 11/2019, 8/2020, 9/2020 Effective Date 10/1/2020; Oxford Only: 11/1/2020
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2020 P 1289-3 Program Prior Authorization/Regulatory Medication HIV Pre-exposure Prophylaxis (PrEP) Zero Dollar Cost Share – generic tenofovir disoproxil fumarate 300 mg P&T Approval Date 11/2019, 8/2020, 9/2020 Effective Date 10/1/2020; Oxford only: 11/1/2020 . 1. Background: The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition.1 Once-daily oral treatment with Truvada® (emtricitabine/tenofovir disoproxil fumarate) is approved by the US Food and Drug Administration (FDA) for use as PrEP in persons at risk of sexual acquisition of HIV infection. Several studies reviewed by the USPSTF found that tenofovir disoproxil fumarate alone was also effective as PrEP and CDC guidelines note that, given these trial data, tenofovir disoproxil fumarate alone can be considered as an alternative regimen for high-risk heterosexually active men and women and persons who inject drugs.1-3 This program is designed to meet Health Care Reform requirements which require coverage of effective antiretroviral therapy, which includes tenofovir disoproxil fumarate or Truvada, at zero dollar cost share if being used for PrEP and criteria are met. 2. Coverage Criteria: A. Coverage at zero dollar cost share of generic tenofovir disoproxil fumarate 300 mg will be approved based on both of the following criteria: 1. Member is taking generic tenofovir disoproxil fumarate 300 mg as effective antiretroviral therapy for PrEP -AND- 2. Generic tenofovir disoproxil fumarate 300 mg will be used as part of a comprehensive prevention strategy including other prevention measures Authorization will be issued for zero copay with deductible bypass for 12 months.
    [Show full text]
  • EVOTAZ (Atazanavir Or Cobicistat) to Pregnant Rats and Rabbits (See Data)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Assess creatinine clearance (CLcr) before initiating treatment. Consider These highlights do not include all the information needed to use EVOTAZ alternative medications that do not require dosage adjustments in patients safely and effectively. See full prescribing information for EVOTAZ. with renal impairment. (5.3) • When cobicistat, a component of EVOTAZ, is used in combination with a EVOTAZ (atazanavir and cobicistat) tablet, for oral use tenofovir disoproxil fumarate (tenofovir DF)-containing regimen, cases of Initial U.S. Approval: 2015 acute renal failure and Fanconi syndrome have been reported. (5.4) • When used with tenofovir DF, assess urine glucose and urine protein at ---------------------------RECENT MAJOR CHANGES--------------------------­ baseline and monitor CLcr, urine glucose, and urine protein. Monitor serum Indications and Usage phosphorus in patients with or at risk for renal impairment. Coadministration Indications (1.1) 07/2020 with tenofovir DF is not recommended in patients with CLcr below 70 Dosage and Administration mL/min or in patients also receiving a nephrotoxic agent. (5.4) Laboratory Testing Prior to Initiation and During • Chronic kidney disease has been reported during postmarketing surveillance Treatment with EVOTAZ (2.1) 04/2020 in patients with HIV-1 infection treated with atazanavir, with or without Recommended Dosage (2.2) 07/2020 ritonavir. Consider alternatives in patients at high risk for renal disease or Not Recommended During Pregnancy (2.5) 04/2020 with preexisting renal disease. Monitor renal laboratory tests prior to therapy Contraindications (4) 04/2020 and during treatment with EVOTAZ. Consider discontinuation of EVOTAZ Warnings and Precautions in patients with progressive renal disease. (5.5) Immune Reconstitution Syndrome (5.11) 07/2020 • Nephrolithiasis and cholelithiasis have been reported.
    [Show full text]
  • Dolutegravir-Abacavir-Lamivudine (Triumeq)
    © National HIV Curriculum PDF created September 24, 2021, 7:23 pm Dolutegravir-Abacavir-Lamivudine (Triumeq) Table of Contents Dolutegravir-Abacavir-Lamivudine Triumeq Summary Drug Summary Key Clinical Trials Resistance Key Drug Interactions Drug Summary Dolutegravir-abacavir-lamivudine is a single-tablet regimen that is used primarily for treatment-naïve individuals. It has high potency, a relatively robust barrier to resistance (due to the dolutegravir component), and few drug interactions. It may be especially advantageous for individuals with renal insufficiency or risk factors for renal disease or osteoporosis, as it avoids the use of tenofovir DF. In certain treatment- experienced individuals, dolutegravir-abacavir-lamivudine may provide an option for switch or simplification of therapy. Abacavir can cause a life-threatening hypersensitivity reaction in individuals who are HLA-B*5701 positive; all patients need to undergo testing for HLA-B*5701 prior to receiving dolutegravir-abacavir- lamivudine and those who test positive for HLA-B*5701 should not receive this single tablet regimen. Dolutegravir blocks tubular secretion of creatinine and therefore causes a small increase in serum creatinine in the first 4 to 8 weeks of use; this increase is benign and does not indicate a change in true creatinine clearance. Key Clinical Trials In antiretroviral-naïve individuals, dolutegravir plus abacavir-lamivudine demonstrated superior virologic responses when compared with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine [SINGLE], with superiority largely driven by the greater tolerability of the dolutegravir plus abacavir-lamivudine regimen. In a comparison of 2 NRTIs plus either dolutegravir or raltegravir in treatment-naïve patients, virologic responses in the subset of patients who received dolutegravir plus abacavir-lamivudine were equivalent to those receiving raltegravir plus either tenofovir DF-emtricitabine or abacavir-lamivudine [SPRING-2].
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Adults and Adolescent Living With
    Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Adult and Adolescent Guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIVinfo Web site (http://hivinfo.nih.gov). What’s New in the Guidelines? August 16, 2021 Hepatitis C Virus/HIV Coinfection • Table 18 of this section has been updated to include recommendations regarding concomitant use of fostemsavir or long acting cabotegravir plus rilpivirine with different hepatitis C treatment regimens. June 3, 2021 What to Start • Since the release of the last guidelines, updated data from the Botswana Tsepamo study have shown that the prevalence of neural tube defects (NTD) associated with dolutegravir (DTG) use during conception is much lower than previously reported. Based on these new data, the Panel now recommends that a DTG-based regimen can be prescribed for most people with HIV who are of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with persons of childbearing potential, to allow them to make an informed decision.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Management of Hiv Infection
    MANAGEMENT OF HIV INFECTION Federal Bureau of Prisons Clinical Guidance September 2018 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Referenced Program Statement versions within this document are for informational purposes only. Please refer to the most current version of the referenced Program Statement. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp Federal Bureau of Prisons Management of HIV Infection Clinical Guidance September 2018 WHAT’S NEW IN THIS DOCUMENT? This document updates the December 2017 version of the BOP Clinical Guidance on the Management of HIV Infection. Treatment information throughout this document was updated to be in line with the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents issued by the Department of Health and Human Services (DHHS) in 2018. NOTEWORTHY CHANGES INCLUDE REVISIONS IN THE FOLLOWING AREAS: • INDICATIONS FOR HIV TESTING: An opt out strategy of voluntary testing for HIV infection is recommended for all inmates, regardless of sentencing status, including new intakes and those already established in the population who have not declined testing. • MENINGOCOCCAL VACCINE: Adults with HIV infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY (MCV4), available as Menactra® or Menveo®, at least 2 months apart, and then revaccinated every 5 years.
    [Show full text]
  • BIKTARVY (Bictegravir, Emtricitabine, and Tenofovir
    HIGHLIGHTS OF PRESCRIBING INFORMATION or below 15 mL per minute who have no antiretroviral treatment These highlights do not include all the information needed to use history. (2.3) BIKTARVY safely and effectively. See full prescribing information • Hepatic impairment: BIKTARVY is not recommended in patients for BIKTARVY. with severe hepatic impairment. (2.4) BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) ----------------------DOSAGE FORMS AND STRENGTHS--------------------- tablets, for oral use Tablets: 50 mg of bictegravir (equivalent to 52.5 mg of bictegravir Initial U.S. Approval: 2018 sodium), 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide (equivalent to 28 mg of tenofovir alafenamide fumarate). (3) WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B -------------------------------CONTRAINDICATIONS------------------------------- See full prescribing information for complete boxed warning. BIKTARVY is contraindicated to be co-administered with: • dofetilide. (4) Severe acute exacerbations of hepatitis B have been • rifampin. (4) reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing -----------------------WARNINGS AND PRECAUTIONS------------------------ emtricitabine (FTC) and/or tenofovir disoproxil fumarate • Immune reconstitution syndrome: May necessitate further evaluation (TDF), and may occur with discontinuation of BIKTARVY. and treatment. (5.3) Closely monitor hepatic function in these patients. If • New onset or worsening renal impairment:
    [Show full text]
  • Emtricitabine and Tenofovir Alafenamide
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------DOSAGE AND ADMINISTRATION----------------------­ These highlights do not include all the information needed to use • Testing: Prior to initiation of DESCOVY, patients should be tested for DESCOVY safely and effectively. See full prescribing information hepatitis B virus infection, and estimated creatinine clearance, urine for DESCOVY. glucose and urine protein should be obtained. (2.1) • ® Recommended dosage: One tablet taken once daily with or without DESCOVY (emtricitabine and tenofovir alafenamide) tablets, for food in patients with body weight at least 25 kg and a creatinine oral use clearance greater than or equal to 30 mL per minute. (2.2) Initial U.S. Approval: 2015 • Renal impairment: DESCOVY is not recommended in patients with WARNING: POST TREATMENT ACUTE EXACERBATION OF estimated creatinine clearance below 30 mL per minute. (2.3) HEPATITIS B ----------------------DOSAGE FORMS AND STRENGTHS--------------------­ See full prescribing information for complete boxed warning. Tablets: 200 mg of FTC and 25 mg of TAF (3) • DESCOVY is not approved for the treatment of chronic -------------------------------CONTRAINDICATIONS------------------------------­ hepatitis B virus (HBV) infection. Severe acute None. exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have -----------------------WARNINGS AND PRECAUTIONS-----------------------­ discontinued products containing emtricitabine (FTC) • Immune reconstitution syndrome: May necessitate further evaluation and/or tenofovir disoproxil fumarate (TDF), and may occur and treatment.(5.2) with discontinuation of DESCOVY. Hepatic function should • New onset or worsening renal impairment: Assess creatinine be monitored closely in these patients. If appropriate, clearance, urine glucose, and urine protein in all patients before initiation of anti-hepatitis B therapy may be warranted.
    [Show full text]
  • Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3114-3 Program Step Therapy Medications Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate), efavirenz/emtricitabine/tenofovir disoproxil fumarate (generic Atripla) P&T Approval Date 9/2018, 3/2020, 3/2021 Effective Date 5/1/2021; Oxford only: 5/1/2021 1. Background: This program requires the provider to validate that the member is not an appropriate candidate for any of the following before providing coverage for Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate): Dovato (dolutegravir/lamivudine), Symfi or Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate), Triumeq (abacavir/dolutegravir/lamivudine), Isentress/Isentress HD (raltegravir) plus Cimduo (lamivudine/tenofovir disoproxil fumarate), Tivicay (dolutegravir) plus Cimduo (lamivudine/tenofovir disoproxil fumarate), or Juluca (dolutegravir/rilpivirine). For the treatment of HIV, antiretroviral regimens generally consist of three drugs –a two drug nucleoside reverse transcriptase inhibitor (NRTI) backbone in combination with a third drug from one of the following classes: integrase strand transfer inhibitor (INSTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI) with a pharmacokinetic (PK) enhancer. Data also support the use of the two-drug regimen, dolutegravir plus lamivudine, for initial treatment. Based on improved virologic outcomes and tolerability, INSTIs are recommended as first-line treatment options in most patients.1 Atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.2 2. Coverage Criteriaa: A. HIV 1. Atripla or generic Atripla will be approved based on both of the following: a.
    [Show full text]
  • Reference ID: 4219844
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ CONTRAINDICATIONS ----------------------------- These highlights do not include all the information needed to use • Previous hypersensitivity reaction to dolutegravir. (4) DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR • Coadministration with dofetilide. (4) ALAFENAMIDE TABLETS safely and effectively. See full prescribing information for DOLUTEGRAVIR, EMTRICITABINE AND ----------------------- WARNINGS AND PRECAUTIONS ----------------------- TENOFOVIR ALAFENAMIDE TABLETS. • Hepatotoxicity has been reported in patients receiving a dolutegravir- containing regimen. Monitoring for hepatotoxicity is recommended. DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR (5.1) ALAFENAMIDE tablets, for oral use • Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been WARNING: POST TREATMENT ACUTE EXACERBATION OF reported. Discontinue dolutegravir, emtricitabine and tenofovir HEPATITIS B alafenamide tablets and other suspect agents immediately if signs or See full prescribing information for complete boxed warning. symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. (5.2) • Tenofovir alafenamide, one component of dolutegravir, • Immune reconstitution syndrome has been reported in patients treated emtricitabine and tenofovir alafenamide tablets, is approved for the with combination antiretroviral therapy. (5.5) treatment of chronic hepatitis
    [Show full text]